



King's Research Portal

Document Version
Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Mehta, V., Ma, Y., Wijesuriya, N., De Vere, F., Howell, S., Elliott, M., Mannakkara, N., Hamakarim, T., Wong, T., O'Brien, H., Niederer, S., Razavi, R., & Rinaldi, C. A. (in press). Enhancing Transvenous Lead Extraction Risk Prediction: Integrating Imaging Biomarkers into Machine Learning Models: Using imaging to predict risk following TLE. *Heart rhythm : the official journal of the Heart Rhythm Society*.

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 **Enhancing Transvenous Lead Extraction Risk Prediction: Integrating Imaging Biomarkers into**
2 **Machine Learning Models**

3

4 **Short Title:** Using imaging to predict risk following TLE.

5

6 **Authors:**

7 **Vishal S Mehta MBBS^{1,2} – corresponding author**

8 YingLiang Ma PhD^{2,3}

9 Nadeev Wijesuriya MBBS^{1,2}

10 Felicity DeVere MBBS^{1,2}

11 Sandra Howell MBBS^{1,2}

12 Mark K Elliott MBBS PhD^{1,2}

13 Nilanka N Mannakara MBBS^{1,2}

14 Tatiana Hamakarim^{1,2}

15 Tom Wong PhD^{1,2,4}

16 Hugh O'Brien PhD²

17 Steven Niederer DPhil^{2,4}

18 Reza Razavi PhD^{1,2}

19 Christopher A Rinaldi MD FHRS^{1,2}

20

21 **Affiliations:**

22 ¹ Cardiology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK

23 ² School of Biomedical Engineering and Imaging Sciences, King's College London, UK

24 ³ School of Computing Sciences, University of East Anglia, Norwich, UK

25 ⁴ National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK

26

27 **Correspondence:**

28 Dr Vishal Mehta

29 School of Biomedical Engineering and Imaging Sciences

30 St Thomas' Hospital

31 London, SE1 7EH, U.K.

32 Email: vishal.mehta@kcl.ac.uk

33

34 **Keywords**

35 Transvenous lead extraction; TLE; Complications; Machine Learning; Artificial intelligence

36

37 **Sources of funding**

38 The authors are supported by the Wellcome/EPSRC Centre for Medical Engineering

39 (WT203148/Z/16/Z).

40

41 **Disclosures**

NW receives fellowship funding from the British Heart Foundation (FS/CRTF/22/24362). VM has received fellowship funding from Siemens and Abbott. NNM is in receipt of fellowship funding from Heart Research UK (grant no. RG2701) and Abbott. YM receives research funding from UK Engineering and Physical Sciences Research Council (EP/X023826/1). SAN acknowledges support from the UK Engineering and Physical Sciences Research Council (EP/M012492/1, NS/A000049/1, and EP/P01268X/1), the British Heart Foundation (PG/15/91/31812, PG/13/37/30280, SP/18/6/33805), US National Institutes of Health (NIH R01-HL152256), European Research Council (ERC PREDICT-HF 864055) and Kings Health Partners London National Institute for Health Research (NIHR) Biomedical Research Centre. CAR receives research funding and/or consultation fees from Abbott, Medtronic, Boston Scientific, Spectranetics and MicroPort outside of the submitted work.

42 **Abstract – 250 words**

43

44 **Background:**

45 Machine learning (ML) models have been proposed to predict risk related to transvenous lead extraction
46 (TLE).

47

48 **Objective:**

49 We tested if integrating imaging data into an existing ML model increases its ability to predict major
50 adverse events (MAE: procedure-related major complications and procedure-related deaths) and lengthy
51 procedures (≥ 100 minutes).

52

53 **Methods:**

54 We hypothesised certain features: i) lead angulation ii) coil percentage inside the superior vena cava (SVC),
55 and iii) number of overlapping leads in the SVC, detected from a pre-TLE plain anterior-posterior (AP)
56 chest x-ray (CXR) would improve prediction of MAE and long procedure times. A deep-learning
57 convolutional neural network was developed to automatically detect these CXR features.

58

59 **Results:**

60 1050 cases were included, with 24 (2.3%) MAEs. The neural network was able to detect: i) heart border
61 with 100% accuracy, ii) coils: 98% accuracy, iii) acute angle in the right ventricle and SVC: 91% and 70%
62 accuracy respectively. The following features significantly improved MAE prediction: i) $\geq 50\%$ coil within
63 the SVC, ii) ≥ 2 overlapping leads in the SVC, and iii) acute lead angulation. Balanced accuracy (0.74 to
64 0.87), sensitivity (68% to 83%), specificity (72% to 91%), and area under the curve (AUC) (0.767 to 0.962)
65 all improved with imaging biomarkers. Prediction of lengthy procedures also improved: balanced accuracy
66 (0.76 to 0.86), sensitivity (75% to 85%), specificity (63% to 87%), and AUC (0.684 to 0.913).

67

68 **Conclusion:**

69 Risk prediction tools integrating imaging biomarkers significantly increases the ability of ML models to
70 predict risk of MAE and long procedure time related to TLE.

71

72 **Abbreviations**

73 ML - Machine Learning

74 TLE - Transvenous lead extraction

75 SVC - Superior Vena Cava

76 AP - Anterior Posterior

77 CXR - Chest X-Ray

78 MAE - Major Adverse Event

79 AUC - Area Under the Curve

80 CIED - Cardiac Implantable Electronic Device

81 DL - Deep Learning

82 CNN - Convolutional Neural Network

83 GSTT - Guy's and St Thomas' Trust

84 ELECTRa - European Lead Extraction ConTRolled

85 IQR - Interquartile Range

86 ADASYN - Adaptive Synthetic

87 JSC - Jaccard Similarity Coefficient

88 SNN - Spiking Neural Network

89 SVM - Support Vector Machines

90 RF - Random Forest

91 ICD - Implantable Cardioverter Defibrillator

92

93 **Introduction**

94

95 The progressive rise of cardiac implantable electronic devices (CIEDs) over the last 20 years has been
96 mirrored by an increased requirement for lead extraction. Transvenous lead extraction (TLE) remains a
97 safe procedure in the majority of cases, with the incidence of procedure related major complications
98 quoted as 1.6% in a systematic review of 18,433 patients¹. Whilst procedural success is high, there are an
99 increasing number of patients at risk of adverse outcomes due to a high burden of comorbidities and
100 multiple previous device interventions². Improved risk stratification of patients based on likelihood of
101 risk of adverse outcomes, and procedural complexity, is important for informed patient consent and
102 appropriate resource allocation basis³.

103

104 Multiple risk scores have been developed; however, their predictive capability is constrained by the rarity
105 of adverse events, the binary nature of pre-procedural risk factors, and variation in methodology^{4,5}. We
106 previously published a risk assessment model to predict risk of adverse events utilising machine learning
107 methods. The study used patient-level data derived from the ESC EORP Electra registry of 3,555 patients
108 undergoing TLE in 73 centres across Europe⁶. This ML model's predictive capability was tested against
109 an independent registry of >1,000 patients, and its performance compared to an established clinical risk
110 score – the Electra Registry Outcome Score (EROS)³.

111

112 We hypothesised that geometric features extracted from a pre-procedure plain anterior-posterior (AP)
113 chest radiograph (CXR) would improve this ML model's predictive capability. In this study, we have the
114 following aims: i) develop a deep learning (DL-) based, convolutional neural network (CNN) to
115 automatically detect geometric features relevant to risk of TLE from pre-procedure CXRs, ii) evaluate if
116 these features improve the previously published ML model's performance, and iii) assess whether the same
117 methods could predict long procedure times (which acted as a proxy for procedure complexity).

118

119 **Methods**

120

121 The database collection and analysis were approved by the Institutional Review Board of Guy's and St
122 Thomas' Hospital.

123

124 *Study Populations and outcome definitions*

125

126 A prospectively collected database of all consecutive patients undergoing TLE between October 2000 and
127 November 2019 were recorded on a computer database at Guys' and St Thomas' NHS Foundation Trust
128 (GSTT), a high-volume UK TLE centre was used for chest radiograph data. 1171 patients underwent
129 TLE in this period. The intended outcome from the ML model was pre-procedural identification of
130 patients at high risk of negative outcomes and complex procedures. The outcome of major adverse event
131 – defined as a composite of procedure related major complication and procedure related death – was
132 selected as the ground truth to capture this goal. These were defined in both datasets by the consensus
133 statement in the ELECTRa dataset^{3,8} (supplementary table 1). Each MAE was only counted once per
134 patient (i.e. if a major complication and death were recorded for the same patient, this was only counted
135 as 1 MAE). Prolonged procedure time, defined as time taken from procedure start to removal of targeted
136 leads lasting >100 minutes. This cut-off was chosen as it was the 75th percentile of procedural duration
137 (i.e., 25% of the cases were longer than 100 minutes).

138

139 *Statistics*

140

141 Categorical variables were compared with a Chi-squared test or Fisher's exact test. Normally distributed
142 data was analysed using independent samples t-test. Non-normally distributed continuous data was
143 analysed using the Kruskal-Wallis one-way analysis of variance test. The results are presented as
144 mean±standard deviation for normally distributed variables and median [interquartile range (IQR)] for

145 non-normally distributed variables. Categorical variables are presented as number of patients (% of
146 group). These analyses were performed using R version 1.3.1093.

147

148 The definitions of the performance measures used to describe the accuracy of the neural network to detect
149 the geometric features, and the ML- model to predict MAE, are described in table 1. The Jaccard similarity
150 coefficient (JSC) was used as a simple statistical measure for testing the correlation between an identified
151 individual geometric feature on a CXR and the binary outcome of MAE⁹. As the dataset is known to be
152 imbalanced⁶, an Adaptive Synthetic (ADASYN) sampling technique was used to balance the datasets and
153 calculate the JSC¹⁰. The relative importance of each feature in the final model is represented by an F-
154 score, which is a way to rank the features based on their contribution to the final prediction, i.e. the higher
155 the F-score value, the greater that particular feature contributes to the model's prediction of risk. The F-
156 score for each feature should be considered in relation to the score of other features contributing to the
157 model. Balanced accuracy, sensitivity, specificity, and receiver operating characteristic curves were used
158 to assess the predictive capability of the ML-model.

159

160 Overview of original machine learning study

161 Previously, we have published a a ML-based risk stratification tool trained using the ELECTRa registry to
162 predict risk of MAEs in 3555 patients undergoing TLE and tested this on an independent registry of 1171
163 patients ⁶. ML models were developed, including a self-normalising neural network (SNN), stepwise
164 logistic regression (“stepwise model”), support vector machines (SVM) and random forest (RF) model.
165 These were compared to the Electra Registry Outcome Score (EROS) for MAEs ³. ML techniques were
166 similar to EROS by balanced accuracy (ML-model: 0.74 vs EROS: 0.70) and superior by area under the
167 curve (ML-model: 0.764 vs EROS: 0.677). Whilst there was an improvement in accuracy, this was
168 incremental, and hypothesised that integrating imaging biomarkers into this model would improve its
169 predictive capability.

170

171 Rationale on radiograph feature selection

172

173 A combination of known risk factors and senior clinical opinion was considered when choosing
174 appropriate features from a plain CXR. In previously published data, the presence of an ICD lead, an
175 increased number of leads extracted^{3,11}, and likelihood of lead encapsulation¹² are established risk factors
176 that could be detected from a plain CXR. The most common cause of procedure related major
177 complication or death is a tear in the SVC¹³ and therefore identifying accurate proxies for a model of the
178 SVC and the location of leads and coils in relation to this was considered essential. It was also
179 hypothesised that lead-to-lead interaction (measured by whether the leads were overlapping), or an acute
180 (i.e., a <90 degree) angulation of the lead within the SVC or the myocardium were important factors to
181 consider. An acute angle was defined as an angle between 0 and 90 degrees of the lead itself at the locations
182 of the SVC or the right ventricle (supplementary figure 1).

183

184 These geometric features were combined with the baseline characteristics of the patients as illustrated in
185 table 2 to feed into a ML model to predict risk of MAE. The model was based on the pre-procedural
186 features in a previously published ML-model trained on the ELECTRa registry and tested on the GSTT
187 database⁶. All features considered and included in the final ML models, including and excluding geometric
188 features are in supplementary table 2. An XGBoost classifier was chosen due to its high performance with
189 imbalanced datasets and binary classifications, and is an ensemble learning method that combines the
190 predictions of multiple models to produce a stronger prediction¹⁴. Due to the relative infrequency of
191 MAEs observed, leave-one-out cross validation was used¹⁵. For comparison, the added value of the
192 geometric features was tested against the model using only the pre-procedure characteristics in table 2 (i.e.,
193 excluding the geometric features from the CXR).

194

195 Overview of imaging biomarker detection framework

196

197 The deep learning framework to automatically identify the geometric features has been previously been
198 described in detail¹⁶, a summary of the process is illustrated in figure 1 and outlined below:

199

200 I) *Identification of the approximate location of the SVC*

201

202 The SVC is not readily identifiable on a CXR, unless contrast is injected, however, it is possible to
203 determine an approximate course in relation to heart anatomy. Using known common approximate
204 models of heart anatomy, we were able to approximate the location of the SVC. The SVC location is
205 approximately half the height and one third of the width of the heart region (supplementary figure 2). This
206 was validated by overlaying 3D anatomy models extracted from 20 pre-procedure CT scans. In order to
207 use this automated SVC location in a CXR, the heart region needed to be detected. A transfer learning
208 approach was used to detect the heart region which was based on a modified VGG16 model. 70% of the
209 CXRs were used for training and 30% were used for accuracy testing.

210

211 II) *Detection of lead and coils*

212

213 To segment the leads and coils from the CXRs, a U-Net convolutional network was trained and tested on
214 the CXR dataset. To semi-automate this, a vessel enhancement filter¹⁷ was used to extract all wire-like
215 objects and the resultant image was automatically binarized. An experienced clinician manually removed
216 features not leads or coils, which acted as the “ground truth” for the U-net model to train on 737 CXRs
217 to automatically extract coils and leads, whilst ignoring other objects such as ECG leads, ribs, and the
218 generator. To improve detection with poor quality images, the contrast or brightness of these images were
219 reduced by a factor between 0.6 and 0.9 to create an additional 1474 training images.

220

221 III) *Extracting geometric features*

222

223 A centreline extraction method was used to precisely identify the lead or coil detected that was present in
224 the SVC¹⁸. In this process, a binarized image of the detected coils and leads was skeletonised and a one-
225 pixel wide object is created. A contour finding algorithm and wire reconstruction method was used to
226 determine the course of the lead and compute location and angulation of the leads or coil, and determine
227 if they were overlapping^{19,20}. The two points of angulation interest were at the point of entry into the
228 SVC or within the RV (supplementary figure 1). The ground truth was the manual labelling of all angles
229 of the leads in two positions: the entry point of the SVC and inside the RV. Overlapping leads was defined
230 as the centrelines of the leads overlapping with each other at least once.

231

232 **Results**

233

234 *Baseline characteristics*

235

236 The overall cohort included 1,151 patients, of which 1,050 had pre-procedure chest radiographs available
237 for use in the current analysis (table 2). There were 24 (2.3%) MAEs, of which the most common major
238 complication was cardiac avulsion (n=12, 1.2%) (supplement table 3). In total, there were 484 cases with
239 complete procedure duration data available, of these 123 (25.4%) had a long procedure time. Overall,
240 73.5% (n=772) were male with mean age at explant of 65.3±14.5 years and mean LVEF of 44.8±14.3%.
241 Median lead dwell time was 5.30 (1.80-10.00) years and the plurality of devices explanted were dual
242 chamber pacemakers (n=370, 35.3%) followed by ICDs (n=297, 28.3%). In total 2,246 leads were
243 explanted, with a mean of 2.14 leads per procedure. 443 defibrillator leads were explanted, of which 219
244 (49.4%) were dual coil leads. The majority of extractions were for infective indications (n=562, 54.1%), of
245 which most were for local infections (n=372, 52.6%). The most common comorbidities were heart failure
246 (n=414, 40.7%) followed by hypertension (n=406, 40.4%). In total 206 (20.1%) patients had CKD, with
247 a median baseline creatinine of 92.00 [77-119.3] md/dl.

248

249 Automated detection performance

250

251 The performance of the DL neural network to automatically detect the geometric features is described in
252 table 3. This was excellent in all areas with the exception for acute angle detection in the SVC.

253

254 Geometric feature selection and deep-learning model for risk assessment

255

256 The geometric features assessed and their respective JSC values are illustrated in table 4. 143 cases had an
257 acute angle in the RV. Greater than 50% of a coil in the SVC combined with ≥ 2 overlapping leads in the
258 SVC had a very sensitive JSC value, and resulted in a much higher performance and contribution overall
259 to the model to predict MAE rather than separating the features (see supplementary table 4). Therefore,
260 the following geometric features were included in the final model: i) $>50\%$ coil in the SVC and ≥ 2
261 overlapping leads in the SVC, and ii) acute angle in the RV.

262

263 Ability of model to predict major adverse event and long procedure time.

264

265 The most important features in the model excluding geometric features are dwell time, LVEF and eGFR
266 (supplementary figure 3) for predicting MAE. The presence of a dual coil lead was only the 10th most
267 important feature in the model excluding geometric features. In comparison, two geometric features were
268 the 2nd and 12th most important features in the model including the CXR data (figure 2A). The most
269 important pre-procedural clinical factor remained lead dwell time, however the presence of $\geq 50\%$ of a
270 coil in the SVC and ≥ 2 overlapping leads had a similar predictive value for MAE as dwell time (F-score:
271 19.7 vs 18.7). An acute angle in the RV was almost as important as LVEF (F-score: 7.16 vs 8.53) and
272 more important than male gender (F-score: 7.07). Infective factors were of high relevance (endocarditis
273 F-score: 16.85, local infective indication F-score: 15.21).

274

275 There was a significant improvement in the model's ability to predict MAE with CXR data (table 5).
276 Balanced accuracy improved from 0.75 to 0.87, sensitivity improved from 69% to 83%, specificity
277 improved from 72% to 91%, and AUC improved from 0.767 to 0.962 (figure 2B). There was no significant
278 difference in model performance when using the ground truth data compared to automated CXR feature
279 detection (supplementary figure 4).

280

281 With respect to long procedure time, the most important pre-procedural clinical factors were endocarditis
282 (F-score 12.95), respiratory disease (F-score: 11.77) and local infection (F-score: 7.01) (figure 3A). The
283 most predictive feature was >50% of coil in the SVC and ≥ 2 overlapping leads from the pre-procedural
284 CXR of (F-score: 48.11). Balanced accuracy improved from 0.76 to 0.86, sensitivity improved from 75%
285 to 87%, specificity improved from 63% to 85%, and AUC improved from 0.684 to 0.913 (figure 3B).

286

287 We explored whether inclusion of lateral chest radiographs increased the predictive capability of the
288 model, however there was no significant improvement, with balanced accuracy increasing from 0.91 to
289 0.92 and the AUC from 0.962 to 0.969 (see [supplementary file 2](#)).

290

291 **Discussion**

292

293 This is the first deep learning derived model integrating imaging biomarkers to predict risk following TLE.
294 main findings are:

- 295 1. Convolutional neural networks can automatically, and accurately, detect key geometric features
296 relevant to lead extraction, particularly the SVC location, the course of a lead, lead angulation,
297 percentage of coil in the SVC, and whether leads overlap.
- 298 2. Imaging biomarkers integrated into an independently tested ML-model significantly improved its
299 predictive capability.
- 300 3. ML can improve prediction of potentially lengthy procedures.

301

302 Relevance of risk stratification

303 Undertaking a lead extraction procedure with the appropriate expertise, tools and in the correct setting is
304 one of the cornerstones of reducing procedural risk. Extensive data has shown that high volume lead
305 extraction centres perform better compared with low volume centres and patients with known risk factors
306 who have a lead extraction in a low volume centre have poorer outcomes reinforcing the fact that high
307 volume operators should perform higher risk procedures^{1,21}. TLE is a resource intensive and expensive
308 procedure, which is often poorly reimbursed relative to their economic costs to the health institution²².
309 Within this context, risk stratification scores are a helpful tool for the heart team when triaging patients
310 appropriately pre-procedure.

311

312 There have been several published risk stratification tools, primarily using a combination of expert
313 consensus and logistic analysis. Bontempi et al developed the “LED risk score”, which identified number
314 of extracted leads within a procedure, lead age, dual-coil lead and presence of vegetation as increasing the
315 likelihood of a complex procedure²³. Kancharla et al derived a risk score including an ICD lead >5 years
316 old, and pacemaker lead >10 years old. The tool was prospectively validated on whether patients should
317 have TLE performed in an operating room or device laboratory⁴. The EROS score developed by Sidhu
318 et al⁷ categorised patients as low (EROS 1), intermediate (EROS 2) and high risk (EROS 3). EROS 3 risk
319 was heavily dependent on lead dwell time – a pacemaker lead >15 years, and ICD lead >10 years from
320 implant. We previously compared the EROS score to a ML-based risk score trained on the ELECTRa
321 database and tested on the dataset used in this study with an AUC of 0.764, however the study concluded
322 that more nuanced and richer pre-procedure data was required to make ML a beneficial tool⁶. This current
323 study has built on that conclusion and shown features extracted from a plain CXR – a simple investigation
324 that should be performed in all patients undergoing lead extraction – significantly improves risk prediction.
325 This is particularly marked in the geometric features related to the SVC and the congestion of leads within
326 it. TLE has a high procedural success rate and complications remain low, so an excellent AUC is necessary

327 to provide the necessary sensitivity and specificity for added value. The AUC improvement from 0.76 to
328 0.96 in this study demonstrates such an improvement. An AUC score of between 0.9-0.99 is considered
329 excellent²⁴.

330

331 Clinical perspectives

332 Better risk stratification tools have the potential to ensure stronger mitigation and minimise the risk of
333 MAE. The value of such a risk tool may be useful for both infective and non-infective indications of lead
334 extraction. For infective indication, there is always a class I indication to extract infected material²⁵,
335 however it is not always clear who is likely to be at significantly higher risk of an adverse event. For non-
336 infective indications, the evidence for lead extraction is less strong with clinical consensus and patient
337 preference primarily determining whether a malfunctioning lead should be extracted or left redundant
338 when a new lead is implanted. Currently, the data regarding the potential harms of abandoning leads in
339 such circumstances is unclear, and weighing benefits and risks is a largely a joint decision between the
340 cardiologist and the patient²⁶. Having a highly sensitive and specific test would help quantify that risk
341 better and allow the decision to be made more objectively. The current study provides the framework for
342 such a test.

343

344 In addition, the ability of the current model to determine those at higher risk of a long procedure times
345 has clinical utility. Traditional risk factors for complex procedures, in particular the presence of an ICD,
346 markers of infection and respiratory disease, were strong influencers in the model. It is likely that these
347 patients had more complex general anaesthetic requirements in view of their endocarditis and respiratory
348 disease, and the presence of a coil increased the number of tools and time required to extract the material.
349 These factors are important when determining resource and time allocation, and whether the procedure
350 should occur in the operating room, hybrid or device laboratory.

351

352 Future perspectives

353 A previous study by Howard et al has shown the utility of neural networks to accurately identified the
354 model of pacemakers and defibrillators²⁷; however, this is the first deep learning framework to
355 automatically detect CXR and lead related features increasing the risk of MAE following TLE. We have
356 demonstrated that novel methods can improve the prediction of an adverse outcome by integrating a
357 ubiquitous and inexpensive investigation, such as a CXR. All patients should have a CXR pre-TLE, and
358 this data, combined with baseline clinical features, can be routinely integrated into pre-procedure planning.
359 Such techniques can also potentially be used in cross-sectional imaging which have greater spatial
360 resolution of the three-dimensional course of a lead and coil, particularly in relation to the SVC; however,
361 contrast enhanced computerised tomography (CT) imaging using current deep learning techniques is
362 challenging due to the high intensity of artefacts from the lead and coils. Real time fluoroscopy and motion
363 tracking could also give added information on lead-to-lead or lead-to-SVC interaction giving a far greater
364 understanding on how lead kinetics affect procedural risk²⁰.

365

366 Overall, the whole process is computationally inexpensive. The computer vision algorithm works within
367 500 milliseconds (ms) to identify the coil and lead route, as well calculating angles. The prediction
368 algorithm (XGBoost) performs the prediction in 1000ms to produce the prediction once the relevant
369 baseline demographic and imaging data are uploaded. We anticipate that this tool can be used before or
370 during the “heart team” meeting, where a decision is made on the appropriateness and location of any
371 lead extraction procedure.

372

373 **Limitations**

374 The high imbalance between the MAE (2.4%) and non-MAE (97.6%) cases means much larger datasets
375 are required to increase the confidence in our results. To mitigate this, leave-one-out validation, and ML-
376 algorithms (i.e., XG Boost and ADASYN sampling technique) which perform well with imbalanced data
377 were used. Certain low frequency but traditional high-risk features of patients undergoing TLE, such as
378 lead calcification were not included in the analysis as they were not consistently recorded. The risk

379 prediction model was applied retrospectively which may introduce bias, and a prospective validation study
380 would mitigate this. Whilst the neural network to detect most geometric features was robust, it was sub-
381 optimal in detecting acute angles in the SVC due to the low frequency of such cases, and this feature was
382 therefore not included in the final model. A plain AP CXR was used, however for 3-dimensional distances
383 between individual leads, a higher volume of lateral CXRs may be included in future analyses.

384

385 **Conclusion**

386 This is the first study to use imaging biomarkers to assess risk related to TLE. We have developed a high-
387 performing automated deep learning algorithm to accurately extract geometric features from a plain
388 anterior posterior chest radiograph. By integrating this imaging data to an existing ML-model, we have
389 significantly improved prediction of adverse events and potentially complex procedures related to TLE.

390

391 **References**


- 392 1. Pelargonio G, Narducci ML, Manzoli L, et al.: Safety of transvenous lead extraction according to
393 centre volume: A systematic review and meta-analysis. *Europace* 2014; 16:1496–1507.
- 394 2. Mehta VS, Elliott MK, Sidhu BS, et al.: Long-term survival following transvenous lead extraction:
395 Importance of indication and comorbidities. *Heart Rhythm* 2021; 18:1566–1576.
- 396 3. Bongiorno MG, Kennergren C, Butter C, et al.: The European Lead Extraction ConTrolled (
397 ELECTRa) study : a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead
398 Extraction Outcomes. 2017; :2995–3005.
- 399 4. Kancharla K, Acker NG, Li Z, et al.: Efficacy and Safety of Transvenous Lead Extraction in the
400 Device Laboratory and Operating Room Guided by a Novel Risk Stratification Scheme. *JACC Clin
401 Electrophysiol* [Internet] Elsevier, 2019; 5:174–182. Available from:
402 <https://doi.org/10.1016/j.jacep.2019.01.001>
- 403 5. Jacheć W, Polewczyk A, Polewczyk M, Tomasiak A, Kutarski A: Transvenous Lead Extraction
404 SAFETY Score for Risk Stratification and Proper Patient Selection for Removal Procedures Using
405 Mechanical Tools. *J Clin Med* 2020; 9:361.
- 406 6. Mehta VS, O'Brien H, Elliott MK, et al.: Machine learning–derived major adverse event prediction
407 of patients undergoing transvenous lead extraction: Using the ESC EHRA EORP European lead
408 extraction ConTrolled ELECTRa registry. *Heart Rhythm Elsevier B.V.*, 2022; 19:885–893.
- 409 7. Sidhu BS, Ayis S, Gould J, et al.: Risk stratification of patients undergoing transvenous lead
410 extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European
411 lead extraction ConTrolled ELECTRa registry analysis. *EP Europace* [Internet] 2021; 23:1462–
412 1471. Available from: <https://doi.org/10.1093/europace/euab037>
- 413 8. Maytin M, Jones SO, Epstein LM: Long-term mortality after transvenous lead extraction. *Circ
414 Arrhythm Electrophysiol United States*, 2012; 5:252–257.
- 415 9. Chung NC, Miasojedow BZ, Startek M, Gambin A: Jaccard/Tanimoto similarity test and estimation
416 methods for biological presence-absence data. *BMC Bioinformatics BioMed Central Ltd.*, 2019; 20.

- 417 10. Institute of Electrical and Electronics Engineers: Neural Networks, 2008, IJCNN 2008, (IEEE
418 World Congress on Computational Intelligence), IEEE International Joint Conference on : date,
419 1-8 June 2008.
- 420 11. Segreti L, Rinaldi CA, Claridge S, et al.: Procedural outcomes associated with transvenous lead
421 extraction in patients with abandoned leads: An ESC-EHRA ELECTRa (European Lead
422 Extraction ConTRolled) Registry Sub-Analysis. *Europace* 2019; 21:645–654.
- 423 12. Kołodzińska A, Kutarski A, Koperski Ł, Grabowski M, Malecka B, Opolski G: Differences in
424 encapsulating lead tissue in patients who underwent transvenous lead removal. *Europace Oxford*
425 University Press, 2012; 14:994–1001.
- 426 13. Tulecki Ł, Polewczyk A, Jacheć W, et al.: A study of major and minor complications of 1500
427 transvenous lead extraction procedures performed with optimal safety at two high-volume referral
428 centers. *Int J Environ Res Public Health MDPI*, 2021; 18.
- 429 14. Chen T, Guestrin C: XGBoost: A Scalable Tree Boosting System. 2016; . Available from:
430 <http://arxiv.org/abs/1603.02754>
- 431 15. Sengupta PP, Shrestha S, Berthon B, et al.: Proposed Requirements for Cardiovascular Imaging-
432 Related Machine Learning Evaluation (PRIME): A Checklist: Reviewed by the American College
433 of Cardiology Healthcare Innovation Council. *JACC Cardiovasc Imaging*. Elsevier Inc., 2020, pp.
434 2017–2035.
- 435 16. Ma, Y., Mehta, V.S., Rinaldi, C.A., Hu, P., Niederer, S., Razavi, R. (2023). Automatic Detection of
436 Coil Position in the Chest X-ray Images for Assessing the Risks of Lead Extraction Procedures. In:
437 Bernard, O., Clarysse, P., Duchateau, N., Ohayon, J., Viallon, M. (eds) *Functional Imaging and*
438 *Modeling of the Heart. FIMH 2023. Lecture Notes in Computer Science*, vol 13958. Springer,
439 Cham. https://doi.org/10.1007/978-3-031-35302-4_32
- 440 17. Frangi AF, Niessen WJ, Vincken KL, Viergever MA: Multiscale vessel enhancement filtering. In
441 Wells WM, Colchester A, Delp S, eds: *Medical Image Computing and Computer-Assisted*
442 *Intervention — MICCAI'98 Berlin, Heidelberg: Springer Berlin Heidelberg, 1998, pp. 130–137.*


- 443 18. Ma YL, Alhrishy M, Narayan SA, Mountney P, Rhode KS: A novel real-time computational
444 framework for detecting catheters and rigid guidewires in cardiac catheterization procedures. *Med*
445 *Phys John Wiley and Sons Ltd*, 2018; 45:5066–5079.
- 446 19. Suzuki S, be K: Topological structural analysis of digitized binary images by border following.
447 *Comput Vis Graph Image Process [Internet]* 1985; 30:32–46. Available from:
448 <https://www.sciencedirect.com/science/article/pii/0734189X85900167>
- 449 20. Ma Y, Zhou D, Ye L, Housden RJ, Fazili A, Rhode KS: A Tensor-Based Catheter and Wire
450 Detection and Tracking Framework and Its Clinical Applications. *IEEE Trans Biomed Eng IEEE*
451 *Computer Society*, 2022; 69:635–644.
- 452 21. Sidhu BS, Gould J, Bunce C, et al.: The effect of centre volume and procedure location on major
453 complications and mortality from transvenous lead extraction: an ESC EHRA EORP European
454 Lead Extraction ConTRolled ELECTRa registry subanalysis. *Europace*. 2020 Nov 1;22(11):1718-
455 1728. doi: 10.1093/europace/euaa131. PMID: 32688392.
- 456 22. Gould J, Sidhu BS, Porter B, et al.: Financial and resource costs of transvenous lead extraction in a
457 high-volume lead extraction centre. *Heart* 2020; l:931–937.
- 458 23. Bontempi L, Vassanelli F, Cerini M, et al.: Predicting the difficulty of a lead extraction procedure:
459 The LED index. *Journal of Cardiovascular Medicine* 2014; 15:668–673.
- 460 24. Carter J V., Pan J, Rai SN, Galandiuk S: ROC-ing along: Evaluation and interpretation of receiver
461 operating characteristic curves. *Surgery (United States) Mosby Inc.*, 2016; 159:1638–1645.
- 462 25. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al.: 2017 HRS expert consensus statement on
463 cardiovascular implantable electronic device lead management and extraction. *Heart Rhythm*
464 *Elsevier B.V.*, 2017; 14:e503–e551.
- 465 26. Poole JE, Gleva MJ, Mela T, et al.: Complication rates associated with pacemaker or implantable
466 cardioverter-defibrillator generator replacements and upgrade procedures: Results from the
467 REPLACE registry. *Circulation* 2010; 122:1553–1561.

- 468 27. Howard JP, Fisher L, Shun-Shin MJ, et al.: Cardiac Rhythm Device Identification Using Neural
469 Networks. *JACC Clin Electrophysiol* Elsevier Inc, 2019; 5:576–586.
- 470 28. García V, Mollineda RA, Sánchez JS: Index of balanced accuracy: A performance measure for
471 skewed class distributions. *Lecture Notes in Computer Science* (including subseries *Lecture Notes*
472 *in Artificial Intelligence* and *Lecture Notes in Bioinformatics*) 2009; 5524 LNCS:441–448.
- 473
- 474


Step 1 – Identify approximate location of SVC



Step 2 – lead and coil detection



Step 3 – extracting geometric features




476

477


478 *Figure 1: An overview of the deep learning framework to identify geometric features on a plain anterior-posterior chest*

479 *radiograph.*

A



B



480



481

482 *Figure 2: Machine learning model for predicting MAE. A: Features and their respective weights for predicting MAE. B:*

483 *The receiver operating characteristic (ROC) curve of the ML model for predicting major adverse event (MAE). Blue – the*

484 *ROC curve using a model without imaging data. Green – the ROC curve using a model with imaging.*

485

A**B**

486

487 *Figure 3: Machine learning model for predicting long procedure times. A: Features and their respective weights for*488 *predicting MAE. B: The receiver operating characteristic (ROC) curve of the ML model for predicting major adverse event*489 *(MAE). Blue – the ROC curve using a model without imaging data. Green – the ROC curve using a model with*490 *imaging.*

491

492

493

494 **Tables**

495

496 **Table 1:** Performance measures used to describe results of the neural network and machine learning

497 model to predict major adverse event (MAE).

498

Performance measure	Definition	Formula
Balanced Accuracy	Balanced accuracy, rather than total accuracy, was utilised as the primary performance measure in view of the skewed distribution of outcomes with no MAEs vs those with MAEs – i.e., there were very few cases involving MAEs in both datasets ²⁸ . Using accuracy alone, would over-estimate the ability of the risk stratification method in appropriately identifying the patient risk. Balanced accuracy is the mean accuracy for each class.	$\frac{\text{TPR} + \text{TNR}}{2}$
Precision	Precision is the ability of a model to identify only the relevant objects – i.e., precision is how good the model is at accurately identifying a geometric feature	$\frac{\text{TP}}{\text{TP} + \text{FP}} = \frac{\text{TP}}{\text{All detections}}$
Recall	Recall is the ability of a model to find all the relevant cases – i.e., how many times the model was able to accurately identify a geometric feature	$\frac{\text{TP}}{\text{TP} + \text{FN}} = \frac{\text{TP}}{\text{All ground truths}}$
F1 Score	The F1 score is a method of calculating a mean of precision and recall.	$2 * \frac{\text{Precision} * \text{Recall}}{\text{Precision} + \text{Recall}}$

<p>Jaccard Similarity Coefficient</p>	<p>JSC is a statistical measure for correlating the similarity between binary data samples (defined as sample A and B). M_{11} represents the total number of attributes where sample A and B both have a value of 1. M_{01} represents the total number of attributes where the attribute of A is 0 and the attribute of B is 1. M_{10} represents the total number of attributes where the attribute of A is 1 and the attribute of B is 0.</p> <p>It represents the percent of characteristics found in both samples and found in only one sample, i.e., a Jaccard Similarity of 0.3 means 30% of the characteristics were found in both samples, and 70% were found in only one of the two samples.</p>	$JSC = \frac{M_{11}}{M_{01} + M_{10} + M_{11}}$
---------------------------------------	--	---

499

500 *TPR – True Positive Rate. TNR – True Negative Rate. TP – True Positive. FP – False Positive. FN – False*
501 *Negative.*

502

503 **Table 2:** Baseline characteristics of all subjects in test dataset.

504

	Overall
n	1050
Demographics	
Male (%)	772 (73.5)

Explant Age in Years (mean (SD))	65.30 (14.49)
Device type	
Single chamber PPM (%)	74 (7.1)
Dual Chamber PPM (%)	370 (35.3)
Implantable Cardioverter Defibrillator (%)	297 (28.3)
CRT-Pacemaker (%)	67 (6.4)
CRT-Defibrillator (%)	240 (22.9)
Leads	
Dwell Time in Years (median [IQR])	5.30 [1.80, 10.00]
Active RV lead (%)	546 (24.4)
Passive RV lead (%)	207 (19.7)
Active RA lead (%)	534 (50.9)
Passive RA lead (%)	201 (19.1)
LV lead (%)	234 (22.3)
Single Coil Defibrillator Lead (%)	224 (21.3)
Dual Coil Defibrillator Lead (%)	219 (20.9)
Total number of leads extracted (%)	
1	294 (28.0)
2	444 (42.3)
3	216 (20.6)
4 or more	96 (9.1)
Side of explant	
Left sided (%)	856 (81.5)
Right sided (%)	131 (12.5)
Both sides (%)	63 (6.0)

Extraction Indication	
Non-infective Indication (%)	482 (45.9)
Local Infection (%)	372 (35.5)
Systemic Infection (%)	196 (18.7)
Extraction History	
History of Previous Extraction (%)	118 (11.2)
Co-Morbidities	
IHD (%)	402 (39.6)
Valvular Disease (%)	100 (9.9)
Heart Failure (%)	414 (40.7)
Diabetes Mellitus (%)	174 (17.3)
Hypertension (%)	406 (40.4)
Respiratory Disease (%)	145 (14.4)
CKD (%)	206 (20.1)
ESRF (%)	10 (1.0)
Cardiac Function	
LVEF (mean (SD))	44.77 (14.34)
Biochemistry	
Creatinine ($\mu\text{mol/L}$) (median [IQR])	92.00 [77.00, 119.25]
eGFR (ml/min/1.73 m^2) (mean (SD))	67.47 (20.75)
eGFR<60 (ml/min/1.73 m^2) (%)	391 (37.2)
Peak CRP (mg/L) (median [IQR])	6.00 [2.00, 18.00]

506 *CRP – C-reactive protein. eGFR – estimated glomerular filtration rate. LVEF – left ventricular ejection fraction.*
 507 *ESRF – end stage renal failure. CKD – chronic kidney disease. IHD – ischaemic heart disease. LV – left ventricle. RA*
 508 *– right atrium. RV – right ventricle. CRT – cardiac resynchronisation therapy. PPM – permanent pacemaker. IQR –*
 509 *Interquartile Range.*

510
 511 **Table 3:** The performance of the neural network to detect the feature on the CXR in comparison to the
 512 ground truth. * Ability to detect >75% of the true heart border

513

Geometric Feature	Accuracy	Precision	Recall	F1 score
Detection of heart border*	NA	0.818	1	NA
Detection of coils	0.98	0.98	0.99	0.98
Detection of leads	0.782	0.879	0.836	0.857
Detect acute angle in SVC	0.7	0.833	0.714	0.769
Detect acute angle in RV	0.905	0.969	0.923	0.945

514

515 *SVC – superior vena cava. RV – right ventricle.*

516

517

518 **Table 4:** The geometric feature detected and its respective Jaccard Similarity Coefficient (JSC)

519

Geometric Features	JSC
50% of coil and ≥ 2 overlapping leads inside the SVC	0.35
The acute angle in the RV	0.03
The acute angle near the entry point of the SVC	0.01

520

521 *SVC – superior vena cava. RV – right ventricle.*

522

523

524 **Table 5:** The predictive capability of the machine learning model to predict a major adverse event or
 525 long procedure excluding and including the geometric features from the pre-procedure chest radiograph.
 526

Outcome	Results	Balanced accuracy	Specificity	Sensitivity	Area Under Curve
Major Adverse Event	Excluding Imaging	0.74	0.63	0.62	0.77
	<i>Including Imaging</i>	<i>0.87</i>	<i>0.91</i>	<i>0.83</i>	<i>0.96</i>
Long procedure time	Excluding Imaging	0.76	0.63	0.75	0.684
	<i>Including Imaging</i>	<i>0.86</i>	<i>0.87</i>	<i>0.85</i>	<i>0.913</i>

527

528

529

530


Supplemental Materials

531

532

Supplementary figure 1: Angle location

533



534

535

536

The red angle is the angulation of the lead near the entry point of the SVC and the green lead angle is the one within the RV.

537

538


539

Supplementary figure 2: (a) A medically accurate illustration of the anatomy of the heart. The red box is the region of the heart, and the green box is the location of the SVC. (b) Overlaying 3D anatomy models with the X-ray image. The blue shadow is the 3D model of aorta, left ventricle and the SVC. The red box is the region of the heart, and the green box is the location of the SVC.

540

541

542



543


544

545


546

Supplementary Figure 3: The features for the model excluding imaging data for predicting MAE.

547




B



548

549

550 *Supplementary Figure 4: The features for the model excluding imaging data for predicting MAE using the ground truth*
 551 *data.*



552

553

(a) Using ground truth data

554

555

556 *Supplement Table 1: classification of complications*

557

Classification of Complication	Examples
<i>Major Complication</i>	Death
	Cardiac avulsion or tear requiring thoracotomy, pericardiocentesis, chest tube, or surgical repair
	Vascular avulsion or tear (requiring thoracotomy, pericardiocentesis, chest tube, or surgical repair)
	Pulmonary embolism requiring surgical intervention
	Respiratory arrest or anaesthesia related complication leading to prolongation of hospitalization
	Stroke
	Pacing system related infection of a previously non-infected site
<i>Minor Complication</i>	Pericardial effusion not requiring pericardiocentesis or surgical intervention
	Haemothorax not requiring a chest tube
	Hematoma at the surgical site requiring reoperation for drainage
	Arm swelling or thrombosis of implant veins resulting in medical intervention
	Vascular repair near the implant site or venous entry site
	Hemodynamically significant air embolism
	Migrated lead fragment without sequelae
	Blood transfusion related to blood loss during surgery
	Pneumothorax requiring a chest tube
	Pulmonary embolism not requiring surgical intervention

558

559

560 *Supplement Table 2: Pre-implant features considered in machine learning model excluding and including geometric features from*
561 *chest radiographs.*

562

563 *X – not included in final model. ✓ - was included in final model.*

564

All Features Considered	Included in ML Model (excluding geometric features)	Included in ML Model (including geometric features)
Age at Explant	✓	✓

Male Sex	✓	×
Lead dwell time (Months)	×	×
Lead dwell time (years)	✓	✓
Single Coil Defibrillator Lead	✓	✓
Dual Coil Defibrillator Lead	✓	✓
Local Infection (Infected Device/Erosion)	✓	✓
Systemic infection (Sepsis/Infective Endocarditis)	X	X
Creatinine (mcg/dL)	×	×
C-Reactive Protein (mg/dL)	X	×
eGFR (ml/min/m2)	✓	✓
History of Previous Extraction	X	×
Left Ventricular Ejection Fraction	✓	✓
Diabetes	×	×
Coronary Artery Disease	×	×
Heart Failure	✓	✓
Renal Impairment	✓	×
Chronic Respiratory Disease	✓	✓
Hypertension	×	×
Coronary Artery Bypass Grafting	×	×
Ischaemic Heart Disease	×	×
Peripheral Vascular Disease	×	×
Cerebrovascular Accident	×	×
Cumulative Co-Morbidity Burden	×	×

Total Leads Extracted		×	×
Device Type		×	×
Device Indication		×	×
Pacing lead type extracted - "Atrial Passive", "Atrial Active", "RV Passive", "RV Active", "LV Lead"		×	×
Non-infective extraction indication - "Lead Displacement", "Lead Failure", "Lead Malfunction", "Venous stenosis", "Pain", "Functional Lead Removal", "Other", "Sprint Fidelis lead extraction"		×	×
Chest radiograph feature	Acute RV lead angle	X	✓
	>50% coil in SVC	X	✓
	Acute angle near SVC entry point	X	✓

565

566 *Supplement Table 3: Categorisation of procedure related major adverse events (MAEs).*

567

Major adverse events	Number (%)
Death	1 (0.1)
Cardiac avulsion or tear requiring thoracotomy, pericardiocentesis, chest tube, or surgical repair	12 (1.2)
Vascular avulsion or tear (requiring thoracotomy, pericardiocentesis, chest tube, or surgical repair)	10 (1.0)
Stroke	2 (0.2)
Pacing system related infection of a previously non-infected site	2 (0.2)

568

569 *Note – Please note that the total number of major adverse events (MAEs) is greater than total number of cases with MAEs in the*
 570 *analysis, as events are adjusted and only counted once, i.e. a patient may have had two MAEs from the lead extraction procedure,*
 571 *however this is counted as one MAE.*

572

573 *Supplementary table 4: Table outlining the relative contribution of the features to the model's predictive algorithm, and the*
 574 *performance of the model for major adverse events.*

575

Outcome	Feature	F-score	Balanced accuracy	Specificity	Sensitivity	Area Under Curve
Major Adverse Event	Combined feature of ≥ 2 overlapping leads and $>50\%$ coil in the SVC	19.2	0.87	0.91	0.83	0.96
	≥ 2 overlapping leads only	2.4	0.8	0.78	0.79	0.798
	$>50\%$ of coil in SVC only	8.3	0.83	0.83	0.81	0.868

576

577 *SVC – Superior Vena Cava*

578